drugset / Trial / NCT00113347
Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 1
Completed
10 enrolled
M.D. Anderson Cancer Center
Aventis Pharmaceuticals · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest safe dose of the drugs OSI-774 and docetaxel that can be given together along with radiation treatment for advanced head and neck cancer.
Timeline
- Start
- 2005-04
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Erlotinib | Small molecule | 100 mg | — |
| Subject | Erlotinib | Small molecule | 125 mg | — |
| Subject | Erlotinib | Small molecule | 150 mg | — |